COVID-19 Treatment

What Is COVID-19?

COVID-19 is caused by SARS-CoV-2, a highly transmissible respiratory coronavirus first identified in late 2019. Since then it has caused hundreds of millions of infections worldwide. In most healthy adults the illness is self-limiting and resembles a moderate upper respiratory infection, but certain populations — including adults over 65, immunocompromised individuals, those with diabetes, obesity, chronic lung or heart disease, and unvaccinated persons — face significantly higher risk of severe illness, hospitalization, and death. Current circulating variants continue to evolve, and updated booster vaccines remain one of the most effective tools for preventing serious outcomes.

SARS-CoV-2 enters host cells primarily by binding the angiotensin-converting enzyme 2 (ACE2) receptor via its spike protein. The virus then undergoes rapid replication in the upper and lower respiratory tract. In high-risk individuals this can trigger an exaggerated inflammatory response, leading to cytokine storm, acute respiratory distress syndrome (ARDS), multi-organ dysfunction, and, in some cases, long-term complications collectively referred to as Long COVID. According to the CDC and IDSA, early antiviral therapy is the most powerful intervention available to prevent progression to severe disease.

Telehealth is an ideal care setting for mild-to-moderate COVID-19 because it keeps infected patients safely at home rather than exposing others in a waiting room. At Innocre Telehealth, your board-certified provider evaluates patients in Maryland, Washington, and Delaware for antiviral eligibility, reviews relevant medical history and current medications, and — when clinically appropriate — e-prescribes antivirals directly to your local pharmacy, all during the same-day visit.

Common Symptoms

How Innocre Treats COVID-19 Online

The cornerstone of early COVID-19 treatment for high-risk patients is oral antiviral therapy, which must be initiated within 5 days of symptom onset. Nirmatrelvir/ritonavir (Paxlovid) is the preferred agent per NIH and IDSA guidelines. The original EPIC-HR trial showed an approximately 89% reduction in hospitalization or death in unvaccinated high-risk adults when started early. Real-world studies in vaccinated populations have shown a more modest 25–45% reduction in hospitalization, with the greatest benefit seen in older adults and those with multiple risk factors. During your visit, your provider reviews your complete medication list — Paxlovid (the ritonavir component) carries significant drug–drug interactions with statins, certain antiarrhythmics, immunosuppressants, and oral contraceptives (efficacy reduced for the duration of the course and approximately 2 weeks after) — and adjusts the treatment plan accordingly. Molnupiravir (Lagevrio) is now considered a third-line option per current NIH guidance, after Paxlovid and IV remdesivir, reserved for patients who cannot take Paxlovid due to drug interactions and cannot access remdesivir; it is not recommended in pregnancy.

A positive COVID-19 test result — whether a home rapid antigen test or a PCR — is required before an antiviral prescription can be issued. your provider will review your test result during the visit, assess your risk factors and current health status, and determine eligibility under current IDSA and HHS guidelines. Supportive care guidance is also provided: symptom management with acetaminophen or ibuprofen, adequate hydration, rest, and pulse oximetry monitoring at home for patients with oximeters. Patients in Maryland, Washington, and Delaware can receive e-prescriptions sent directly to their preferred pharmacy.

Paxlovid rebound — a return of COVID-19 symptoms or a new positive test approximately 2–8 days after completing the 5-day course — occurs in a minority of patients and is typically mild. your provider discusses rebound risk management during your visit and provides guidance on monitoring. Patients with Long COVID symptoms (brain fog, persistent fatigue, post-exertional malaise lasting more than 12 weeks) are referred to appropriate specialist care and supported with a structured follow-up plan.